Olanzapine (Zyprexa, Zyprexa Zydis, or in combination with
fluoxetine Symbyax) is an atypical antipsychotic, approved by the FDA for
the treatment of: schizophrenia on 1996-09-30 [1];
depressive episodes associated with bipolar disorder, as part of the Symbyax formulation,
on 2003-12-24[2]; acute manic episodes and maintenance treatment in bipolar
disorder on 2004-01-14[3]. Off-label uses are listed below. The olanzapine
formulations are manufactured and marketed by the pharmaceutical company Eli Lilly
and Company, whose patent for olanzapine proper expires in 2011. Read
more about Zyprexa..